Mizuho Securities analyst Benjamin Chaiken has maintained their bullish stance on PENN stock, giving a Buy rating on January 24.Invest with ...

Leerink Partners analyst Michael Cherny reiterated a Hold rating on Progyny (PGNY – Research Report) on January 28 and set a price target of ...

Roche Holding AG said profit will probably outpace sales growth this year as the Swiss drugmaker works to keep research costs in check and looks for deals to build its pipeline of experimental ...

(NYSE:MRK), a global healthcare leader, finds itself at a crossroads as it navigates challenges in its China Gardasil business while capitalizing on opportunities in pulmonary arterial hypertension ...

BioNTech SE (NASDAQ:BNTX), a biotechnology company renowned for its mRNA technology platform and COVID-19 vaccine success, is navigating a crucial phase in its evolution. With a market capitalization ...

Eculizumab biosimilar Elizaria demonstrates long-term safety and efficacy comparable with the reference product Soliris in ...

Elevance Health posted $418 million in profit for the fourth quarter of 2024, a figure that surpassed Wall Street's ...

SK Hynix CFO Kim Woohyun said that the outlook for memory demand in 2025 was clouded by inventory adjustments, protective ...

The latest report by Future Market Insights highlights a promising outlook for the plug-in hybrid electric vehicle (PHEV) ...

JPMorgan CFO Jeremy Barnum acknowledged on the post-earnings call with analysts that there was "tension" between macro risks and uncertainties and the optimism embedded in asset prices and ...

Net income came in at $2.9 billion, compared with a net loss of $1.8 billion a year ago. On a per-share basis, Citi earned $1.34. Analysts polled by FactSet forecasted $1.22. Revenue rose 12% to ...

Reports $709 million in preliminary1 full-year 2024 U.S. net product revenues $611 million in SYFOVRE® U.S. net product revenues, including $167 million in 4Q 2024$98 million in EMPAVELI® U.S. net ...